Abstract Number: 1673 • 2018 ACR/ARHP Annual Meeting
Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population
Background/Purpose: disease activity in Systemic Lupus Erythematosus (SLE) leads to damage, comorbidities and increased overall mortality. Frequent assessment is needed to adapt patients’ management. The…Abstract Number: 2644 • 2018 ACR/ARHP Annual Meeting
Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a valid index able to measure disease activity while accounting for glucocorticoid (GC)…Abstract Number: 1604 • 2017 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…Abstract Number: 1605 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE
Background/Purpose: In SLE the most common types of organ damage are osteoporotic fractures and cataracts. Other types of organ damage, such as end stage renal…Abstract Number: 1647 • 2017 ACR/ARHP Annual Meeting
A Lupus Low Disease Activity State Is Associated with Reduced Flare, Lower Organ Damage Accrual, and Better Quality of Life in Patients with Systemic Lupus Erythematosus
Background/Purpose: To identify the potential predictors of a lupus low disease activity state (LLDAS), and the relationship between LLDAS and disease flare, organ damage, and…Abstract Number: 889 • 2017 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)
Background/Purpose: Low disease activity (LDA) in lupus patients is increasingly a goal of treatment. For instance, Lupus Low Disease Activity State (LLDAS) attainment is associated…Abstract Number: 1603 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Can We Relax the Definition and Still Achieve Low Risk of SLE-Related Damage?
Background/Purpose: Lupus low disease activity state (LLDAS) is a systemic lupus erythematosus (SLE) outcome measure that combines low disease activity and a 7.5 mg limit…Abstract Number: 790 • 2016 ACR/ARHP Annual Meeting
Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
Background/Purpose: Systemic lupus erythematosus (SLE) has historically lacked clear treat-to-target definitions. The recently reported Lupus Low Disease Activity State (LLDAS) definition, combining disease activity and…Abstract Number: 795 • 2016 ACR/ARHP Annual Meeting
Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?
Background/Purpose: To date, there is no generally accepted definition for remission in SLE, thus a possible goal in the treat-to-target strategy might be low disease…Abstract Number: 1051 • 2016 ACR/ARHP Annual Meeting
Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50) is a reliable and valid index able to measure ≥ 50% improvement in disease…Abstract Number: 1787 • 2016 ACR/ARHP Annual Meeting
Increased Heart Rate Variability Reflects Improvement in Clinical Status of Patients with Systemic Lupus Erythematosus
Background/Purpose: Decreased heart rate variability (HRV) is a sign of potentially serious cardiac morbidity and is known to reflect autonomic dysfunction and inflammatory dysregulation (1).…Abstract Number: 1793 • 2016 ACR/ARHP Annual Meeting
Visceral Adiposity Assessed By DXA in Juvenile-Onset Systemic Lupus Erythematosus: A Correlation with Damage Index and Disease Duration
Background/Purpose: Young woman with lupus (SLE) are at increased risk of early atherosclerosis leading to cardiovascular disease in adult life and consequently higher morbidity and…Abstract Number: 1815 • 2016 ACR/ARHP Annual Meeting
Frequency and Predictors of Attaining the Lupus Low Disease Activity State (LLDAS) in a Multinational SLE Cohort from the Asia Pacific
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable burden from disease activity and damage. A novel clinical treatment target in the…Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…Abstract Number: 766 • 2015 ACR/ARHP Annual Meeting
Clinical and Immunological Characteristics of 150 Systemic Lupus Erythematosus Patients in Urban Jamaica
Background/Purpose: Epidemiological studies in systemic lupus erythematosus (SLE) have been reported in the literature in many countries and ethnic groups. Although SLE in Jamaica has…